68 TW Alexander Drive
PO Box 13628
Research Triangle Park, NC 27709
United States
919 636 4530
https://www.fennecpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 29
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Rostislav Raykov | CEO & Director | 885.07k | N/A | 1976 |
Mr. Robert C. Andrade | Chief Financial Officer | 600.88k | N/A | 1975 |
Mr. Adrian J. Haigh | Chief Operating Officer | 394.19k | N/A | 1959 |
Mr. Mark Gowland | Controller | N/A | N/A | N/A |
Mr. Lei Fang | President of Pharstat Inc | N/A | N/A | N/A |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 5; Compensation: 7.